←
Alex Puissant Lab558 posts
Alex Puissant Lab avatar

Alex Puissant Lab

@LabPuissant

Alex Puissant, Ph.D., is a Principal Investigator in the Hematology-Oncology Department at the Saint Louis Research Institute & Hospital, Paris, France.

◷ Joined January 2019▧ 14 Photos and videos
Scott C Blanchard avatar
⟳ Alex Puissant Lab retweeted
Scott C Blanchard@TheBlanchardLab·Nov 1

Now out in Nature Cell Biology. Five labs brought quantitative proteomics, ribosome profiling, single-molecule imaging, preclinical models and patient-cohort analyses to bear on the unforeseen reach of the K55 dimethylation mark on elongation factor 1A. nature.com/articles/s41556-0…

Stavros George Drakos avatar
⟳ Alex Puissant Lab retweeted
Stavros George Drakos@StavrosDrakos·Oct 30

1/. New publication alert! 🚨 Our lab’s multi-year collaborative work with the labs of @gsducker and @RutterLab just published in @Nature. Our work led to the discovery of a new pathway through which the heart can use lactate to generate energy. nature.com/articles/s41586-0…

Wolf Prize avatar
⟳ Alex Puissant Lab retweeted
Wolf Prize@WolfPrize_·Oct 1

ANNOUNCING THE 2026 WOLF PRIZE LAUREATES IN CHEMISTRY The 2026 Wolf Prize in Chemistry is awarded to Pascal Mayer, Shankar Balasubramanian and David Klenerman for developing impactful, low-cost, next generation DNA sequencing methods for genomic medicine. Their work helped transform DNA sequencing into a technology capable of operating at extraordinary speed and scale. Balasubramanian and Klenerman pioneered a massively parallel sequencing approach that contributed to a million-fold improvement in sequencing speed and cost, helping make it possible to sequence a human genome for under $200. Mayer played a pivotal role in turning those breakthroughs into a practical high-throughput sequencing system, integrating the chemistry, microfluidics, optics and computational components needed to make the technology work at scale. Today, the sequencing platform that grew from this work forms the technological foundation for more than 90% of global sequencing data, powering major advances in genomics and precision medicine. Congratulations to the 2026 Wolf Prize Laureates in Chemistry! @Cambridge_Uni @universitedestrasbourg

Post attachment
Gennaro Napolitano avatar
⟳ Alex Puissant Lab retweeted
Gennaro Napolitano@G__Napolitano·Sep 30

Happy to see our paper, led by outstanding postdoc Alessandra Esposito, out in @Nature today. We uncovered a TBK1/ULK1 signaling pathway that acts as a lysosome quality control mechanism, regulating the FLCN-TFEB axis in response to lysosomal stress Link: rdcu.be/icEViqq6F68a

Post attachment
Jean-Ehrland Ricci avatar
⟳ Alex Puissant Lab retweeted
Jean-Ehrland Ricci@jer_06200·Oct 1

How does metabolism shape anti-tumor immunity and can we use it to make immunotherapy work better? A great new review in @Oncogenesis_ on this rapidly moving field. Many thanks to @LabPuissant @camille_lobry @BenajibaLina , N Fenouille nature.com/articles/s41389-0…

Alex Puissant Lab avatar
Alex Puissant Lab@LabPuissant·Jul 9

Profiling a relapse AML cohort and leveraging in vivo functional genomics, we uncovered an actionable SRRM1–CLK1/4–PAK1 node driving chemoresistance and MAP2K5 missplicing as a key relapse-associated event. Dual PAK1/CLK1/4 inhibition restores chemosensitivity.

Alex Puissant Lab avatar
Alex Puissant Lab@LabPuissant·Jul 9

Excited to share our latest study with @camille_lobry! Using multiple AML models, we identified splicing dysregulation as a key feature of chemoresistance and relapse in AML. @Institut_IRSL @Leukemia_Inst @ScienceTM tinyurl.com/mt932jky

Thrilled to share the publication of our latest piece of research in @ScienceTM, in collaboration with and led by the amazing @LabPuissantand Camille Vaganay Why does acute myeloid leukemia (AML) so often relapse after chemo works at first? tinyurl.com/mt932jky 🧵